Iclepertin治疗精神分裂症认知障碍的3项3期随机对照试验
CONNEX项目纳入1835例18-50岁精神分裂症成人患者,随机接受口服iclepertin 10 mg每日一次或安慰剂治疗26周。iclepertin耐受性良好,不良事件发生率与安慰剂组相近。
要点
- iclepertin 10 mg每日一次治疗26周未显著改善精神分裂症相关认知障碍。
- iclepertin耐受性良好,不良事件发生率与安慰剂组相近。
核心结论
- iclepertin未显著改善精神分裂症成人患者的认知功能,但耐受性良好。
研究设计与样本
- CONNEX-1、CONNEX-2和CONNEX-3为3期随机双盲安慰剂对照试验,在41个国家338个精神科中心开展。
- 纳入18-50岁精神分裂症成人患者,按1:1随机接受口服iclepertin 10 mg每日一次或安慰剂治疗26周,联合标准抗精神病药物治疗。
- 主要终点为第26周MATRICS共识认知成套测验(MCCB)总体复合T评分较基线的变化。
主要发现
- 共1835例患者接受至少一剂试验药物(iclepertin组918例,安慰剂组917例),1602例完成治疗。
- iclepertin组604例(66%)和安慰剂组633例(69%)报告治疗期不良事件。
- 安慰剂组1例患者在治疗期间死亡,判定与试验治疗无关。
关键数值与推荐
- 安全性评估:iclepertin组不良事件604/918例(66%),安慰剂组633/917例(69%)。
临床怎么用
- iclepertin 10 mg每日一次治疗26周未显示对精神分裂症相关认知障碍的显著疗效,不推荐用于改善认知。
- iclepertin耐受性良好,但认知改善证据不足,临床决策需结合其他非药物干预。
局限性
- 原文未报告局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There are no pharmacotherapies available for cognitive impairment associated with schizophrenia (CIAS). The CONNEX programme investigated the efficacy and safety of iclepertin, a glycine transporter-1 (GlyT1) inhibitor, for the treatment of CIAS. METHODS: CONNEX-1, CONNEX-2, and CONNEX-3 were phase 3, randomised, double-blind, placebo-controlled trials conducted across 338 specialist psychiatric centres in 41 countries. Adults aged 18-50 years with schizophrenia were randomised 1:1 using interactive response technology to oral 10 mg iclepertin or placebo once daily for 26 weeks in combination with standard-of-care antipsychotic therapy. Patients, investigators, and trial personnel were masked to treatment assignment. The primary endpoint was change from baseline at week 26 in the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) overall composite T-score. Efficacy analyses included randomly allocated patients, excluding those allocated in error or who discontinued from the trial before receiving treatment. Safety and tolerability assessments included adverse event monitoring in patients who received one or more doses of trial medication. These trials were registered with ClinicalTrials.gov (NCT04846868, NCT04846881, NCT04860830) and are complete. Individuals with lived experience informed the trial designs and selection of outcome measures; they were not involved in the writing process. FINDINGS: Between Sept 8, 2021, and April 24, 2024, 1835 patients were recruited and received at least one dose of trial medication (918 for iclepertin and 917 for placebo); 1602 patients completed treatment. 1207 (66%) of 1836 patients were male and 629 (34%) patients were female. Most patients were either White (903 [49%]) or Asian (558 [30%]), and the majority were not of Hispanic or Latino ethnicity (1238 [67%]). The mean age was 34·7 years (SD 8·8). At week 26, there was no significant difference between treatment groups in the primary endpoint. The adjusted mean difference for iclepertin versus placebo for MCCB overall composite T-score was 0·127 [95% CI -0·396 to 0·650]; p=0·63). On-treatment adverse events were reported in 604 (66%) of 918 and 633 (69%) of 917 patients in the iclepertin and placebo groups, respectively. One patient receiving placebo died during the treatment period; the death was deemed unrelated to the trial treatment. INTERPRETATION: Iclepertin was not associated with significant improvements in cognition in adults with schizophrenia, but it was well tolerated by patients. Findings from CONNEX provide insights into the challenges associated with studying new pharmacotherapies for CIAS. FUNDING: Boehringer Ingelheim.
引用
- Keefe RSE, Harvey PD, Correll CU, et al. Efficacy and safety of iclepertin for cognitive impairment associated with schizophrenia (CONNEX programme): results from three phase 3 randomised controlled trials. Lancet Psychiatry. 2025. PMID: 41233083. doi:10.1016/S2215-0366(25)00296-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。